5. References

  1. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www-micromedexsolutions-com.libproxy.uthscsa.edu/ (cited: February 25, 2021).
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021.  Available at: http://clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed February 25, 2021.
  3. Facts and Comparisons eAnswers [database online]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2021; February 25, 2021.
  4. American Society of Health-System Pharmacists. 2021. AHFS Drug Information® - 2021st Ed. Bethesda, MD. American Society of Health-System Pharmacists®. ISBN-10: 1-58528-654-0, ISBN-13: 978-1-58528-654-6. ISSN: 8756-6028. STAT!Ref Online Electronic Medical Library. https://online.statref.com/document/cQfe8yqMRNqgSGqm4Qo8Qj. Accessed February 25, 2021. 
  5. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. (NIH Publication No. 07-4051). Available at:  http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed February 26, 2021.
  6. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. 2021 report. Available at: https://goldcopd.org/2021-gold-reports/. Accessed February 26, 2021.
  7. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available from: https://ginasthma.org/reports/. Accessed February 26, 2021.
  8. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC). 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020 Dec;146(6):1217-1270. 
  9. Diaz PT, Knoell DL. Chapter 24. Chronic obstructive pulmonary disease. In: Alldredge BK, Corelli RL, Ernst ME, et al, eds. Koda-Kimble and Young’s applied therapeutics: the clinical use of drugs. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2013:601-18.
  10. Self TH, Chrisman CR, Finch CK. Chapter 23. Asthma. In: Alldredge BK, Corelli RL, Ernst ME, et al, eds. Koda-Kimble and Young’s applied therapeutics: the clinical use of drugs.  10th ed. Philadelphia: Lippincott Williams & Wilkins; 2013:565-600.
  11. Bourdet SV, Williams DM. Chapter 44. Chronic obstructive pulmonary disease (Chapter) In: DiPiro JT, Talbert RL, Yee GC, et al. (eds): Pharmacotherapy: a pathophysiologic approach. 11th edition. New York, McGraw-Hill, 2020. Access Pharmacy Website. Available at: https://accesspharmacy-mhmedical-com.ezproxy.lib.utexas.edu/index.aspx. Accessed February 26, 2021.
  12. Albuterol inhalation aerosol (ProAir® HFA) package insert. Teva Respiratory, August 2020.
  13. Albuterol inhalation aerosol (Proventil® HFA) package insert. Merck & Co., Inc., October 2019.
  14. Albuterol inhalation aerosol (Ventolin® HFA) package insert. GlaxoSmithKline, February 2021.
  15. Levalbuterol inhalation aerosol (Xopenex HFA®) package insert. Sunovion Pharmaceuticals Inc., June 2020.
  16. Albuterol inhalation powder (ProAir RespiClick®) package insert. Teva Respiratory, October 2020.
  17. Albuterol inhalation powder (ProAir Digihaler®) package insert. Teva Respiratory, October 2020.
  18. Ipratropium/albuterol (Combivent® Respimat® Inhalation Spray) package insert.  Boehringer Ingelheim Pharmaceuticals, Inc., October 2020.
  19. Ferguson GT, Make B. Management of stable chronic obstructive pulmonary disease. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA. February 2021. (Accessed March 3, 2021.)
  20. Stoller JK. Management of exacerbations of chronic obstructive pulmonary disease. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA. February 2021. (Accessed March 3, 2021.)
  21. Blake K. Review of guidelines and the literature in the treatment of acute bronchospasm in asthma. Pharmacotherapy. 2006;26(9 Pt 2):148S-55S.
  22. Schreck DM. Asthma pathophysiology and evidence-based treatment of severe exacerbations. Am J Health-Syst Pharm. 2006;63(10 Suppl 3):S5-13.
  23. Kelly WH. Risk versus benefit considerations for the β2-agonists. Pharmacotherapy. 2006;26(9Pt2):164S-74S.
  24. Bel EH. Clinical practice. Mild asthma. N Engl J Med. 2013;369(6):549-57.
  25. McCracken JL, Veeranki SP, Ameredes BT, Calhoun WJ. Diagnosis and management of asthma in adults: a review. JAMA. 2017;318(3):279-90.